Translation of glycan profiling from analytical curiosity to strategic platform. Deciphering glycan patterns will allow us to forecast drug efficacy, identify disease biomarkers and design novel therapeutics - transforming glycosylation heterogeneity from nuisance into an engineered feature.
Demand for glycan profiling results is driven by two main needs. Glycans influence protein stability, activity, and immunogenicity. As such, glycan characterization has been developed to ensure batch consistency during biopharmaceutical production. Glycans can also be modified during disease states. As a result, glycan profiling has become important for biomarker and drug target discovery. Glycan analysis is being leveraged more often during drug development and manufacturing pipelines as glycans are thought to be one of the main drivers of disease states and are considered a critical quality attribute (CQA) of therapeutic proteins.
Fig. 1 Schematic representation of the preparation process for glycomics analysis in mass spectrometry biomarkers research.1,5
Glycosylation is amongst the most prevalent classes of post-translational modifications that regulate protein folding processes, trafficking within the cell, and interactions with other proteins. Glycans can sterically modulate protein activity, change their charge or bind specific receptors found on target cells. Glycosylation plays an important role in many processes such as white blood cell signaling, cell-cell binding, etc. Glycosylation patterns have been found to be altered in cancer, protein misfolding diseases, and autoimmune diseases. Due to the large variability in structure caused by glycosylation's template free mechanism, glycans can precisely control protein activity.
Structural glycan analysis alone is not sufficient to elucidate function. Detailed correlations between carbohydrate structures and biological functions can be achieved with combined analytical methods and functional assays. Structural analysis can provide information about composition, branching and linkage which all affect how glycans will interact with their targets. With this information it may be possible to predict if a glycan will trigger certain cellular functions such as ADCC or how many ligands must be expressed on a cell surface to initiate receptor binding. Once structure is linked to function, one can begin to modify glycoproteins to change their function or utilize structural information to understand disease related glycan changes.
Table 1 Structure-Function Relationships in Glycan Biology
| Structural Feature | Functional Consequence | Biopharmaceutical Implication |
| Sialylation patterns | Circulatory half-life modulation | Pharmacokinetic optimization |
| Fucosylation status | Effector function engagement | Therapeutic efficacy tuning |
| Branching architecture | Receptor binding affinity | Target specificity enhancement |
Applications of glycan profiling today include research for drug discovery and development from initial profiling of lead compounds to stability and quality control following drug release. Glycoproteins used as therapeutics must be glycan profiled to ensure a consistent glycosylation pattern as variation in this structure can cause variations in safety and efficacy of the drug. Glycomic analysis also allows the identification of disease-associated glycosylation changes such as cancer, neurodegenerative diseases, and genetic disorders. Glycan profiling is being applied to systems biology studies to help create maps of glycosylation in normal and disease settings. Glycan profiling is also being applied in the glycoengineering of cell lines to aid in the production of therapeutics as well as creation of glycan-targeted therapeutics.
Profiling glycosylation is critical during development and manufacturing of biopharmaceuticals. Glycan profiling provides an analytical tool throughout development stages including cell line development, upstream process development and optimization, and continued process verification. Glycoproteins produced for therapeutic use often contain a mixture of glycans attached to them. Glycan profiling allows for characterization of these glycans. Understanding glycosylation allows for structure/function relationship to be elucidated. In addition, glycan profiling allows for comparisons between glycoforms to determine cell line suitability, upstream process robustness, and continued batch release.
Modifications in carbohydrates are regarded as CQAs as they can significantly impact the structure, activity and PK properties of biotherapeutics. Glycosylation is one type of post-translational modification that creates heterogeneity in protein molecules. Processing enzymes present in host cell line as well as cell culture conditions and downstream processing steps could introduce heterogeneity in glycan processing. Therefore, glycan characterization becomes an important aspect of quality by design paradigm and glycosylation profile should meet pre-defined acceptance criteria to assure clinically reproducible performance.
Glycans attached to biotherapeutics regulate activity by modulating protein-receptor interaction, immunogenicity and clearance. Sialic acids capping glycans increase circulation time of therapeutic proteins by preventing their uptake in the liver. High mannose glycans can lead to rapid clearance of therapeutic proteins by binding to mannose receptors. Non-human glycans can be immunogenic and potentially dangerous. Fucosylation and galactosylation level of antibody therapeutics also play a role in their effector functions such as antibody dependent cell mediated cytotoxicity and complement dependent cytotoxicity which affect their potency.
Agencies require full glycan characterization as part of biopharmaceutical development and submission packages. Information on carbohydrate content, structure and microheterogeneity should be submitted in regulatory filings. Points of glycosylation, oligosaccharide structure and monosaccharide composition have been agreed to be characterized as part of the development of quality attributes for the drug substance and drug product during ICH harmonization. The analytical methods used to determine glycosylation should also be validated for these applications. These methods need to be proven to be accurate and reproducible when used to confirm batch-to-batch consistency as well as during comparability studies. Conditions for stability studies should also evaluate glycans to ensure that changes in storage conditions do not negatively alter their structure during the life of the product.
Glycan profiling should be performed during antibody discovery and development and carried through to commercial production. Therapeutic antibody safety and function depend directly on their glycan profiles. Glycan profiling involves analysis of the Fc N-linked glycans found on therapeutic antibodies. The process of glycan profiling supports your decision making for cell line selection and assists you in developing production processes while ensuring product control for regulatory approval and batch consistency.
Fc N-glycans also modulate effector functions through their impact on how the antibody interacts with immune effector cells and complement proteins. Levels of core fucosylation impact binding affinity to the Fcγ receptor expressed on NK cells, and therapeutic antibodies with low levels of fucose elicit higher ADCC activity. Terminal galactosylation affects CDC and sialylation can dampen inflammation. The correlation between glycosylation patterns and antibody activities allow for rational modifications of therapeutic antibodies for specific clinical applications with balanced immunogenicity.
Antibody glycosylation will inherently be microheterogeneous as a result of step-wise, non-templated processing events carried out by enzymes present in the cell line expression system. Culture conditions like temperature and nutrient availability will affect levels of glycosyltransferase enzymes resulting in batch-to-batch variations in glycoform distribution. Batch variation can affect both efficacy and safety profiles of the drug product. Tight controls and testing during the manufacturing process are critical to ensure batch consistency. Glycan profiling allows for tracking of glycoforms in each batch and identifying shifts in glycosylation that may have an effect on drug efficacy.
Strategies for glycoengineering have been developed to control antibody glycosylation for therapeutic reasons or product quality attributes. Engineering of cell lines can change the expression of glycosyltransferases allowing enrichment of desired glycoforms of interest. Another approach is remodeling glycoforms enzymatically ex vivo. This produces antibodies with only one glycoform and allows for easier characterization of the antibody. Antibody glycoengineering can even be used to remove glycans that will be foreign in humans and elicit an immune response.
Applied to regulatory submissions, glycan profiling can serve as evidence for comparability between biosimilar candidate and innovator product as well as to optimize protein therapeutics beyond industry standard practice. Glycan analysis may also be leveraged to demonstrate that variation in glycosylation, resulting from changes to the manufacturing process, will not impact clinical safety and efficacy of the product. Glycan profiling may also play a role in developing biobetters by rationally modifying glycans to change effector function or immunogenicity.
Although the distribution of glycans attached to the protein backbone should be comparable between the biosimilar and reference product, this must be proven by thoroughly characterizing the carbohydrate content, occupancy at each glycosylation site and microheterogeneity using orthogonal methods. Released glycans profiles, glycosylation site occupancy and monosaccharide composition should be compared directly in regulatory submissions and shown to be analytically equivalent. Small shifts in glycoform distribution should be acceptable if they do not affect clinical performance. Large deviations should be explained by functional and clinical data.
Comparison of structural equivalence and functional equivalence can be performed by linking glycan microarray data with bioactivity data to help demonstrate that structural differences are not clinically relevant. In thorough similarity exercises, mass spec characterization is often coupled with receptor binding and cell potency assays to link structural features to mechanism of action. Analytical assays provide insight into glycan structures while functional assays can assess if differences in glycans affect binding to the target, recruitment of effectors, or immunogenicity to demonstrate that the biosimilar is therapeutically equivalent even with carbohydrate microheterogeneity.
Alterations in the manufacturing process such as changes in cell culture media conditions, scale-up factors, or downstream purification steps may influence glycosyltransferase availability or substrates, leading to changes in glycoform distribution. Having predefined glycan characterization provides acceptance criteria for how much change is allowable and ensures any shifts are within an acceptable range. This can be used to support regulatory filings for such changes with confidence that product performance is unaffected.
Glycan profiling can be leveraged at many points across the biopharmaceutical process development and production continuum. During cell line screening stages, glycan profiling can be used to determine what glycan attributes may influence product function and efficacy. Glycosylation can be tracked throughout production in bioreactors. Glycan profiling can assist with purification development by determining how different process parameters affect glycosylation. Understanding glycans throughout process development allows manufacturers to have the information needed to develop a robust manufacturing process that consistently produces proteins within glycoform specifications.
Upstream and downstream monitoring of glycosylation is performed to help maintain quality throughout the bioprocess. Glycan profiles are monitored during upstream cell culture processes because glycosyltransferase expression is affected by bioreactor nutrient levels and other physiochemical variables that can alter glycosylation of the expressed protein. Downstream purification can also play a role in altering glycans. Monitoring glycosylation during purification steps can aid in maintaining glycan structural integrity and avoid loss of targeted glycoforms. Chromatography and mass spectrometry methods can be implemented for at-line monitoring to allow rapid alteration of the bioprocess to correct glycosylation.
Glycosylation potential depends on cell expression system as different cell lines have different repertoire of glycosyltransferases and processing enzymes. Expression in mammalian cells is typically used for glycoproteins requiring complex glycosylation, but alternate expression systems may be acceptable if only limited glycan structures are required. Culture media and feeding regimens also greatly impact glycan quality by changing sugar nucleotide precursor availability and enzyme expression levels. Optimization of cell culture conditions typically involves screening media supplements and culture timepoints for expression of desired terminal glycans that control potency and clearance.
Glycosylation over time can be monitored to demonstrate stability and consistency of a process. Glycosylation trends monitored across multiple batches can start to reveal small shifts that may point to an underlying unstable process or fluctuating raw materials before they start affecting product quality. Control limits can be established on glycan metrics that allow you to determine what is acceptable and trigger an alert to a team if a distribution falls outside of set ranges. Monitoring glycosylation over time can continually validate your process and help prove consistency of commercial batches.
Profiling glycans can be used as an analytical technique to identify disease-associated glycans, which can be used as disease biomarkers and give mechanistic insight. Glycan profiling allows abnormal glycosylation due to disease states such as cancer, inflammation, and autoimmune diseases to be detected using clinical samples. Glycan biomarkers allow one to correlate disease states to specific glycan changes which can allow early detection and targeted treatment.
Changes in glycosylation have been observed in many diseases and can therefore serve as biomarkers. As glycans play an important role in cell recognition, carbohydrates are involved in many disease processes. Changes include branching patterns, sialylation, and fucosylation among others. Glycosylation changes have been shown to occur throughout the body in the blood serum/plasma as well as at the disease site. Some glycosylation changes can even be detected before disease onset. Monitoring glycosylation can allow disease to be detected early on and can be used to follow disease progression or regression in response to treatment. Glycans can easily be obtained from serum/plasma making them ideal biomarkers.
One common characteristic of cancer is hyper branched β1-6 glycosylation and increased expression of metastasis-associated sialyl Lewis antigens. Inflammation is associated with lower levels of galactosylation and sialylation of acute phase proteins. These inflammatory glycans are disease propagating by maintaining T-cell activation. Glycosylation patterns of IgG, such as agalactosylation have been correlated with autoimmune diseases. Targeting these disease glycans allows for classification of patients and monitoring response to treatment by easily obtained specimens.
Table 2 Glycan Modifications Across Major Disease Categories
| Disease Category | Primary Glycan Modification | Functional Consequence |
| Malignant neoplasms | Hyper-sialylation and branching | Metastatic potential enhancement |
| Chronic inflammation | Decreased galactosylation | Pro-inflammatory signaling amplification |
| Autoimmune pathologies | Agalactosylated immunoglobulins | Loss of anti-inflammatory regulation |
Interactions between host and microbes are highly reliant on glycan recognition that leads to infection or prevention of infection. Pathogens express glycans on their surfaces that are recognized by lectin receptors of immune cells. Recognition of these glycans can lead to induction of protective innate immune responses or progression of microbial invasion and infection. Host glycans are also used by microbes to bind to and enter cells during infection. In addition, pathogens can mimic host glycans to avoid detection. Targeting these carbohydrate interactions can help develop new antimicrobials.
Profiling glycans allows for the accurate determination of carbohydrate changes found within diseases that can be used for patient stratification and biomarker development. Glycan profiling is helping translate basic research into diagnostics by performing a comprehensive analysis of serum, plasma, and tissue biopsies. Disease phenotypes and outcomes can be correlated to glycan biomarkers which can then be used to predict personalized treatment plans and inform clinical decision making for various diseases.
Classification of disease patients. The glycan structures expressed by an individual or a disease group can be used to stratify disease patients into meaningful molecular subsets within an otherwise heterogeneous disease population. These molecular subsets can be defined by unique carbohydrate signatures that are associated with different clinical outcomes. Monitoring glycosylation changes over time. Serial samples can be analyzed to track glycosylation changes over time and follow disease progression and response to treatment.
Glycan biomarkers have been mined based on the knowledge that carbohydrates are extremely sensitive to disease conditions. Diseases can often be distinguished by observing the presence or absence of specific glycans when populations of healthy and diseased individuals are compared. Glycosylation changes can occur early in disease progression, and glycans can be altered due to disease-specific molecular pathways. Monitoring glycan biomarkers can potentially be used as a method of early detection or screening for disease. A panel of glycans can be statistically determined to be correlated with disease based on the observation of a large group of patients.
Technical issues in clinical glycomics involve heterogeneous sample populations, significant pre-analytics differences between samples, and developing appropriate sample preparation methods for glycoprotein enriched matrices. Matrices like serum or plasma often contain hundreds of glycoproteins that require sample preparation steps to provide repeatable results. Variability in normal glycosylation profiles between healthy individuals also requires large patient populations to determine statistically significant changes in disease states. Finally, shipping and storage stability of patient samples can limit large scale multi-center studies.
Omics technologies enable glycomics to integrate with other -omics fields like proteomics, genomics and metabolomics. Glycomics complements other omics technologies because glycosylation is one layer of post-translational modification along with protein expression, genetic regulation, and cellular metabolism. Data sets generated from glycan profiling can be integrated with other omics techniques to understand carbohydrate modifications in the context of the wider biological system. For example, changes in glycosylation may help to explain genomic or proteomic alterations, or vice versa. Integrating glycomics into other omics technologies allows researchers to identify stronger biomarkers and therapeutic targets.
Combining glycomics with proteomics allows site-resolved glycosylation analysis which associates discrete glycans with their respective proteins and peptide linkages. Glycoproteomics allows researchers to move beyond analysis of overall glycan content to determine the role of individual glycoprotein isoforms in pathways and diseases. Associating glycan heterogeneity with protein levels and activity can lead to mechanistic understanding of structural changes affecting enzymatic activities, receptor interactions, and intracellular trafficking. Integration with proteomics also allows more specific biomarker discovery as both protein and glycan structure can be used for diagnostic classification.
Glycomic data are often analyzed in the context of other 'omics data such as genomics, transcriptomics, or metabolomics. In systems biology efforts data are combined to build models of glycosylation pathways and their regulation. This approach helps understand the relationship between glycosyltransferase expression, nucleotide sugar levels, and glycan structures, and how both genetics and the environment affect glycosylation. By integrating and interpreting multi-omics data, researchers can identify control points in glycosylation pathways and link them to other cellular signaling pathways. These analyses are used to understand host glycans in the context of immunity and metabolism on a systems level.
Integration of orthogonal analytical approaches allows leveraging of the strengths of various platforms to more completely characterize glycans than possible with one technique alone. MS provides structural information, chromatography can separate isomers and lectin arrays allow quick screening for motifs. Used together, they allow confirmation of results across techniques, as well as completion of information that may be lacking from one technique. Orthogonal analysis allows for more confidence in both structural identifications and quantitative analysis while also allowing for complete characterization of glycan samples. They can be especially useful for confirming low abundance glycans or unexpected glycans as well as standardizing analysis for clinical applications.
There are significant analytical and logistical hurdles which limit broad adoption of glycan profiling for use during drug discovery, characterization and clinical studies. This is due to both inherent characteristics of glycans as well as limitations of existing technologies. Factors include the structural complexity of glycans themselves, considerable biological variability between individuals, and the lack of broad standardization between laboratories. All of these can affect the reproducibility of results, comparability between experiments, and the ability to translate glycomic findings into practical applications for clinical use or regulatory submissions. Data generated through glycan profiling should therefore be validated where possible and interpreted with caution in the contexts of drug development and disease research.
One of the biggest challenges in glycan analysis is their structural diversity. Glycans often exist as isomers with the same molecular formula but vary in linkage position, anomeric status, or branching structure. Current technologies struggle to separate isomers, and orthogonal separation techniques along with advanced fragmentation techniques are often needed to elucidate glycan structures. The inherent biosynthetic nature of glycans results in significant microheterogeneity, which makes glycan quantitation difficult and often demands multiple dimensions of analysis to fully describe glycan populations found in samples.
Table 3 Challenges in Glycan Structural Analysis and Resolution
| Structural Challenge | Analytical Implication | Resolution Strategy |
| Linkage isomerism | Identical mass, different connections | Tandem mass spectrometry fragmentation |
| Anomeric diversity | α versus β configurations | Chromatographic separation with specific standards |
| Branching variations | Same composition, different topology | Multi-dimensional separation approaches |
Fig. 2 Three types of structural representations for one specific glycan.2,5
Patient-to-patient variations as well as age-dependent and/or disease-induced changes present additional challenges to glycan analysis. It can be difficult to differentiate between glycan changes that are disease-specific and those that are due to normal physiological changes. Age, genetics, metabolism, and environment have all been shown to influence glycosylation. Glycosylation differences due to these confounding factors must be ruled out before establishing a link between glycan structures and disease or other traits. As a result, cohort studies with large numbers of subjects and longitudinal studies that monitor glycan changes over time are required to evaluate glycans as clinical tools.
One of the major issues faced by glycomics is the lack of standardization. There are numerous techniques and workflows for analysis, sample preparation, and data interpretation used between laboratories. Differences in enzyme release efficiency, derivatization chemistry, instrument calibration, etc., create data that are difficult to compare between groups and use in submissions. Additionally, lack of standard reference materials and defined protocols force laboratories to validate their findings with other laboratories. The establishment of reporting guidelines is also an ongoing process.
Glycan profiling was once relegated to a small role as an orthogonal quality attribute tool used for protein therapeutics quality control analysis. Glycan profiling has now become a revolutionary tool that connects structural profiling with biological functionality in both basic research and drug development settings. Applications now include monitoring of glycoprotein biomanufacturing processes, identification of disease-related glycans, and customization of glycoprotein therapeutics for enhanced functionality. Linkage of glycan profiles with proteomics, genomics, and other '-omics' approaches enables glycan structures to be connected to mechanisms of action for various biological functions such as immunogenicity, cellular targeting, and more. Applications of glycans are extending to therapeutic development, patient stratification, and biomarker discovery. The glycoscience field is advancing towards standardization of methods and increased bioinformatics support to realize the goals of precision medicine, ensuring product quality, and understanding carbohydrate-mediated biology.
Advanced glycan profiling plays a critical role in both biopharmaceutical development and disease research. Whether evaluating glycosylation as a critical quality attribute (CQA) in biologics or investigating glycan-based biomarkers in clinical studies, robust analytical workflows are essential for generating reliable, decision-ready data. Our glycan profiling services integrate quantitative LC-based methods, high-resolution mass spectrometry, and orthogonal validation strategies to support research, development, and regulatory-facing applications across the drug development lifecycle.
In biopharmaceutical development, glycosylation can directly influence drug efficacy, safety, pharmacokinetics, and immunogenicity. We support:
For translational and disease-focused research, glycan profiling enables:
By aligning analytical depth with project stage—early discovery, process optimization, comparability assessment, or clinical research—we provide glycan data that directly informs scientific and regulatory decision-making.
Different applications require different analytical strategies. We design customized glycan profiling workflows based on:
Our integrated capabilities may include:
Each workflow is designed to ensure analytical robustness, structural confidence, and reproducibility across studies and batches.
If you require glycan profiling services for biopharmaceutical development, biosimilar assessment, process monitoring, or disease research, our team provides customized, quality-controlled analytical solutions. Contact us to discuss your study objectives, sample requirements, and timelines for comprehensive glycomics analysis and data interpretation.
References
